Open Orphan - Completion of Acquisition
ORPH Wed, 15 Jan 2020, 07:00am GMT
Open Orphan was founded in 2017, with the goal of becoming Europe’s leading rare disease and orphan drug focused pharma services company by a management team with extensive industry and financial expertise.
Industry: Health Care
Contact: +353 (01) 6440007
Dublin 2, Ireland
Cathal Friel, Chief Executive of Open Orphan, discusses the acquisition of hVIVO including the deal itself, management team, and synergies with Open Orphan. hVIVO is a differentiated clinical development services business pioneering human disease models based upon viral challenge and leading the way in the use of human challenge studies to establish early proof-of-concept.